Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Equity Average (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Equity Average for 6 consecutive years, with $360.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average fell 7.79% year-over-year to $360.2 million, compared with a TTM value of $360.2 million through Dec 2025, down 7.79%, and an annual FY2025 reading of $368.7 million, down 6.51% over the prior year.
  • Equity Average was $360.2 million for Q4 2025 at Cytek Biosciences, down from $378.1 million in the prior quarter.
  • Across five years, Equity Average topped out at $424.5 million in Q1 2023 and bottomed at -$7.5 million in Q1 2021.
  • Average Equity Average over 5 years is $348.8 million, with a median of $391.9 million recorded in 2024.
  • The sharpest move saw Equity Average skyrocketed 8298.01% in 2022, then dropped 7.79% in 2025.
  • Year by year, Equity Average stood at $404.3 million in 2021, then grew by 4.14% to $421.0 million in 2022, then fell by 3.97% to $404.3 million in 2023, then decreased by 3.39% to $390.6 million in 2024, then decreased by 7.79% to $360.2 million in 2025.
  • Business Quant data shows Equity Average for CTKB at $360.2 million in Q4 2025, $378.1 million in Q3 2025, and $378.6 million in Q2 2025.